期刊文献+

冠心病合并代谢综合征683例分析 被引量:6

下载PDF
导出
摘要 目的:总结冠状动脉粥样硬化性心脏病(冠心病)合并代谢综合征(metabolic syn-drome,MS)患者的临床特征。方法:对1201例冠心病患者的临床资料进行数理分析。结果与结论:冠心病合并MS的发生率为56.9%,冠心病合并MS与单纯冠心病患者比较,其脑梗死发生率(12.9%比5.2%,P<0.01)、肾损害发生率(28.3%比11.8%,P<0.01)、脑出血发生率(6.1%比2.5%,P<0.01)及病死率(4.5%比2.1%,P<0.05)差异均有统计学意义。冠心病患者合并MS的发生率随患者冠心病病程的延长和发病年龄的增加而呈上升趋势。由此可见,冠心病与MS有密不可分的关系,发生MS后直接影响到患者的预后,而冠心病病程越长,发病年龄越大,MS的发生率越高。
出处 《新医学》 北大核心 2007年第8期512-513,共2页 Journal of New Medicine
  • 相关文献

参考文献7

  • 1中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3055
  • 2曾龙驿,孙卫平.有关代谢综合征定义的争议[J].新医学,2006,37(8):558-559. 被引量:7
  • 3DEEDWANIA P C.Metabolic syndrome and vascular disease.is nature or nurture leading the new epidemic of cardiovascular disease?[J]Circulation,2004,109(1):2-4.
  • 4MALID S,WONG N D,FRANKLIN S S,et al.Impact of the metabolic syndrome on mortality from coronary heart disease,cardiovascular disease,and all causes in United States adults[J].Circulationk,2004,110(10):1245-1250.
  • 5WONG N D,PIO J R,FRANKLIN S S,et al.Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome[J].Am J Cardiol,2003,91(12):1424-1426.
  • 6杨帆.阿司匹林抵抗与心血管事件[J].新医学,2003,34(12):769-771. 被引量:4
  • 7SOLYMOSS B C,BOURASSA M G,LESPERANCE J,et al.Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease[J].Coron Artery Dis,2003,14(3):207-212.

二级参考文献30

  • 1[1]Anonymous. Collaborative overview of randomised trials of antiplatelet therapy Ⅰ~Ⅲ . BMJ, 1994, 308(6921-6923): 81-106, 159-168,235 -246.
  • 2[2]Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs. the relationships among dose, effectiveness, and side effect. Chest, 2001, 119(Suppl1): 39S-63S.
  • 3[3]Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke, 1994, 25(12):2331-2336.
  • 4[4]Papps JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. implications for clinical trials and therapy.Arch Patrol Lab Med, 1994, 118(8): 801-804.
  • 5[5]Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspiprin non-responder. a pilot-study including 180 post-stroke patients. Thromb Res, 1993, 71 (5): 397-403.
  • 6[6]Weber AA, Przytulski B, Schanz A, et al. Towards a definition of aspirin resistance: a typological approach. Platelets, 2002, 13 ( 1 ): 37-40.
  • 7[7]Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cycloxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem, 1993, 268(9): 6610-6614.
  • 8[8]Karim S, Habib A, Levy-Toledano S, et al. Cycloxygenase-1 and-2 of endothe lial cells utilize exogenous or endogenous arachidonic acid for transcelluar production of thromboxane. J Biol Chem, 1996, 271(20):12042-12048.
  • 9[9]Vane JR, Bakhle YS, Botting RM. Cycloxygenase 1 and 2. Annu Rev Pharmacol Toxicol, 1998, 38: 97-120.
  • 10[10]Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. ASA and Carotid Endarterectomy(ACE)Trial Collaborators. Lancet, 1999, 353(9171): 2179-2184.

共引文献3062

同被引文献45

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部